This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04067336
Recruitment Status : Recruiting
First Posted : August 26, 2019
Last Update Posted : March 15, 2024
Information provided by (Responsible Party):
Kura Oncology, Inc.